Payment overview · 2025
General Payments
$44,517.57
138 reported records · 25 companies
Healthcare provider profile · identity verified
Rajesh Sam Suri, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FREMONT, CA · NPI 1790700987
Verified facts
What the public records show
CMS Open Payments records show Rajesh Sam Suri, MD received $44,517.57 in general payments during 2025 across 138 reported records.
AngioDynamics, Inc. accounted for 89.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $39,600.00 | 89.0% | 3 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $904.83 | 2.0% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $689.14 | 1.6% | 32 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $657.18 | 1.5% | 14 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $389.67 | 0.9% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $293.38 | 0.7% | 7 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $283.49 | 0.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $256.47 | 0.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $232.54 | 0.5% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$201.77 | 0.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $191.39 | 0.4% | 9 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $147.66 | 0.3% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $114.88 | 0.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $82.34 | 0.2% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $77.96 | 0.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.06 | 0.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.93 | 0.1% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $52.53 | 0.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.00 | 0.1% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $37.95 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.59 | 0.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35.28 | 0.1% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $19.92 | 0.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $19.37 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $19.24 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $39,600.00 | 3 |
| Food and Beverage | $4,541.98 | 134 |
| Travel and Lodging | $375.59 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $30,000.00 | 1 | 2025 |
Source payment records
|
|||||
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $9,600.00 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $416.92 | 7 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $338.95 | 6 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $283.49 | 7 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $253.23 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $232.54 | 9 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $192.47 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $191.39 | 9 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $188.34 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $158.08 | 7 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $147.66 | 2 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $145.00 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $120.25 | 12 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $114.88 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.39 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $82.34 | 4 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $77.96 | 2 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $72.67 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.61 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $40.15 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $37.95 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| BALFAXAR Normalized: balfaxar |
Biological | Octapharma USA, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $12.46 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $9.30 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $4.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 224 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 307 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
79 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
307 | 86 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
224 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 910 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 883 | 259 |
| Losartan Potassium | Losartan Potassium | 720 | 209 |
| Metformin Hcl | Metformin Hcl | 516 | 162 |
| Metoprolol Succinate | Metoprolol Succinate | 493 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 155 |
| Hydrochlorothiazide | Hydrochlorothiazide | 338 | 106 |
| Simvastatin | Simvastatin | 324 | 81 |
| Naproxen | Naproxen | 320 | 123 |
| Jardiance | Empagliflozin | 307 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 121 |
| Furosemide | Furosemide | 266 | 78 |
| Azithromycin | Azithromycin | 265 | 177 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 226 | 102 |
| Eliquis | Apixaban | 224 | 61 |
| Ranolazine Er | Ranolazine | 209 | 55 |
| Gabapentin | Gabapentin | 195 | 64 |
| Lisinopril | Lisinopril | 186 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 75 |
| Carvedilol | Carvedilol | 172 | 50 |
| Omeprazole | Omeprazole | 167 | 44 |
| Allopurinol | Allopurinol | 163 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 41 |
| Atenolol | Atenolol | 157 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 147 | 44 |
| Glipizide | Glipizide | 133 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 126 | 39 |
| Prednisone | Prednisone | 126 | 55 |
| Hydrocortisone | Hydrocortisone | 121 | 63 |
| Potassium Chloride | Potassium Chloride | 118 | 40 |
| Farxiga | Dapagliflozin Propanediol | 109 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 46 |
| Cephalexin | Cephalexin | 96 | 75 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 28 |
| Levofloxacin | Levofloxacin | 92 | 68 |
| Alendronate Sodium | Alendronate Sodium | 90 | 27 |
| Januvia | Sitagliptin Phosphate | 90 | 26 |
| Montelukast Sodium | Montelukast Sodium | 90 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 24 |
| Digoxin | Digoxin | 80 | 25 |
| Linzess | Linaclotide | 79 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 28 |
| Methylprednisolone | Methylprednisolone | 73 | 47 |
| Ibuprofen | Ibuprofen | 71 | 29 |
| Lorazepam | Lorazepam | 71 | 22 |
| Tramadol Hcl | Tramadol Hcl | 71 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 16 |
| Famotidine | Famotidine | 61 | 24 |
| Finasteride | Finasteride | 57 | 16 |
| Ozempic | Semaglutide | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Trazodone Hcl | Trazodone Hcl | 54 | 22 |
| Nitroglycerin | Nitroglycerin | 53 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 52 | 32 |
| Meclizine Hcl | Meclizine Hcl | 51 | 29 |
| Xarelto | Rivaroxaban | 51 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 33 |
| Meloxicam | Meloxicam | 47 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Valsartan | Valsartan | 46 | 11 |
| Metformin Hcl Er | Metformin Hcl | 43 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Metolazone | Metolazone | 40 | 12 |
| Glimepiride | Glimepiride | 39 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 21 |
| Fenofibrate | Fenofibrate | 36 | 14 |
| Risperidone | Risperidone | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 14 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 22 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 24 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Constulose | Lactulose | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 21 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 16 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 14 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $44,517.57 · 138 records | AngioDynamics, Inc. | ABRE, AMPLATZER AMULET, ASSURITY, AVEIR, Attruby, Auryon Laser System 100-120 Vac, BALFAXAR, BIOMONITOR, CAMZYOS, CREON, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FFRct, FREESTYLE LIBRE 3, FUROSCIX, GALLANT, HAWKONE, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, JOT DX, Kerendia, LINZESS, Labosys, LifeStream, LifeVest, MYNX CONTROL, MYNX CONTROL VENOUS, Ozempic, PASCAL, RotarexS 6 F x 135 cm, SHINGRIX, SMARTVEST, TRELEGY ELLIPTA, VERQUVO, VenaCure 1470 Pro, Venclose Maven Catheter, Venovo, WATCHMAN FLX, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error